Pemetrexed

Generic Name
Pemetrexed
Brand Names
Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)
Drug Type
Small Molecule
Chemical Formula
C20H21N5O6
CAS Number
137281-23-3
Unique Ingredient Identifier
04Q9AIZ7NO
Background

Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small ce...

Indication

Pemetrexed is indicated for the treatment of the following conditions:

Non-squamous non-small cell lung cancer (NSCLC)

Malignant pleural mesothelioma

Associated Conditions
Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma
Associated Therapies
Monotherapy
Clinical Trials
Related News

Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer

First Posted Date
2022-10-13
Last Posted Date
2024-12-18
Lead Sponsor
BeiGene
Target Recruit Count
121
Registration Number
NCT05577702
Locations
🇨🇳

Hwa Mei Hospital, University of Chinese Academy of Sciences (Ningbo No Hospital), Ningbo, Zhejiang, China

🇨🇳

The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China

🇨🇳

Beijing Cancer Hospital, Beijing, Beijing, China

and more 11 locations

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

First Posted Date
2022-09-27
Last Posted Date
2024-11-12
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
1170
Registration Number
NCT05555732
Locations
🇺🇸

Florida Cancer Specialists-North, Saint Petersburg, Florida, United States

🇯🇵

Osaka International Cancer Institute, Osaka, Japan

🇺🇸

Southern Cancer Center Pc, Daphne, Alabama, United States

and more 206 locations

A Single-arm Exploratory Study of Neoadjuvant Therapy

First Posted Date
2022-09-06
Last Posted Date
2023-06-08
Lead Sponsor
Jun Liu
Target Recruit Count
28
Registration Number
NCT05527808
Locations
🇨🇳

First Affiliated Hospital, Guangzhou Medical University, Guangzhou, Please Select, China

Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations

First Posted Date
2022-08-19
Last Posted Date
2022-08-19
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
50
Registration Number
NCT05507606
Locations
🇨🇳

Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

Efficacy and Safety of IBI351 in Combination With Sintilimab ± Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation

First Posted Date
2022-08-17
Last Posted Date
2023-05-30
Lead Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Target Recruit Count
144
Registration Number
NCT05504278
Locations
🇨🇳

Jilin Province Cancer Hospital, Jilin, Changchun, China

Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer

First Posted Date
2022-08-16
Last Posted Date
2024-11-08
Lead Sponsor
Gilead Sciences
Target Recruit Count
792
Registration Number
NCT05502237
Locations
🇦🇷

Clínica Viedma, Viedma, Argentina

🇦🇹

Klinikum Klagenfurt am Woerthersee, Klagenfurt Am Woerthersee, Austria

🇺🇸

Eastern CT Hematology and Oncology Associates, Norwich, Connecticut, United States

and more 218 locations

Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

First Posted Date
2022-08-15
Last Posted Date
2024-10-17
Lead Sponsor
Vanderbilt-Ingram Cancer Center
Target Recruit Count
25
Registration Number
NCT05501665
Locations
🇺🇸

Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

First Posted Date
2022-08-12
Last Posted Date
2024-12-06
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
390
Registration Number
NCT05498428
Locations
🇧🇷

Associacao Hospitalar Moinhos de Vento, Porto Alegre, Brazil

🇧🇷

Instituto D Or de Pesquisa e Ensino IDOR, Salvador, Brazil

🇧🇷

Hospital Alemao Oswaldo Cruz, Sao Paulo, Brazil

and more 101 locations

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

First Posted Date
2022-08-09
Last Posted Date
2024-05-02
Lead Sponsor
EQRx International, Inc.
Target Recruit Count
8
Registration Number
NCT05493501
Locations
🇺🇸

Northwest Medical Specialties, PLLC, Tacoma, Washington, United States

🇺🇸

QCCA - Mission Blood & Cancer, Des Moines, Iowa, United States

🇺🇸

Memorial Cancer Institute, Pembroke Pines, Florida, United States

and more 4 locations

A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.

First Posted Date
2022-08-04
Last Posted Date
2024-10-15
Lead Sponsor
Qilu Pharmaceutical Co., Ltd.
Target Recruit Count
632
Registration Number
NCT05487391
Locations
🇨🇳

Shanghai Pulmonary Hospital, Shanghai. China, Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy